NeurogesX (NGSX) Halted Ahead of FDA Panel Meeting
Tweet
Share
E-mailGet Alerts NGSX Hot Sheet
Join SI Premium – FREE
NeurogesX, Inc. (Nasdaq: NGSX) was halted for trading earlier ahead of FDA panel meeting.
The Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) will meet today to review NeurogesX' supplemental New Drug Application (sNDA) for Qutenza(R) (capsaicin) 8% patch for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN).
The Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) will meet today to review NeurogesX' supplemental New Drug Application (sNDA) for Qutenza(R) (capsaicin) 8% patch for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
